StreetInsider.com News Articles

Form 8-K APTARGROUP, INC. For: Sep 21

Mon, 21 Sep 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260921/27085997.html

Aptar and Mass General Hospital team up on nose-to-brain drug delivery

Mon, 14 Sep 2026 17:01:03 -0400

AptarGroup, Inc. (NYSE: ATR) has signed a research collaboration agreement with Massachusetts General Hospital (MGH) to develop a predictive platform for nose-to-brain (N2B) drug delivery, according to a press release from the company.

The collaboration is led by Alice Stanton, PhD, Assistant Professor and Investigator in the Center for Genomic Medicine at Massachusetts General Brigham and Assistant Professor of Neurology at Harvard Medical School. The research will combine in vitro, in vivo and computational technologies to characterize the mechanisms, pathways and kinetics of nose-to-brain transport across a range of molecular classes and physicochemical properties.

The project aims to develop a New Approach

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Mon, 14 Sep 2026 17:00:00 -0400

Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914424839/en/

Aptar and Massachusetts General Hospital Collaborate
</article>
<article>
<h1>Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery</h1>
<p>Mon, 14 Sep 2026 17:00:00 -0400</p>
<p class=

Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914424839/en/